NOVN.CH

97.24

-0.09%↓

NOVN.CH

97.24

-0.09%↓

NOVN.CH

97.24

-0.09%↓

NOVN.CH

97.24

-0.09%↓

NOVN.CH

97.24

-0.09%↓

Search

Lonza Group AG

Open

SectorGezondheidszorg

535.8 1.25

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

524.2

Max

537

Belangrijke statistieken

By Trading Economics

Inkomsten

329M

Verkoop

3.1B

K/W

Sectorgemiddelde

60.853

63.778

EPS

4.31

Dividendrendement

0.71

Winstmarge

10.762

Werknemers

18,686

EBITDA

824M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+23.88% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.71%

2.39%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-3B

39B

Vorige openingsprijs

534.55

Vorige sluitingsprijs

535.8

Nieuwssentiment

By Acuity

11%

89%

10 / 386 Rangschikking in Healthcare

Lonza Group AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 feb 2025, 12:22 UTC

Acquisities, Fusies, Overnames

Lonza Picks BofA, Centerview Partners for Capsules Unit Sale, Bloomberg Law Says, Citing Sources

12 dec 2024, 09:26 UTC

Acquisities, Fusies, Overnames

Lonza Streamlines Business With Capsules Unit Exit -- 2nd Update

12 dec 2024, 07:45 UTC

Acquisities, Fusies, Overnames

Lonza Streamlines Business With Capsules Unit Exit -- Update

12 dec 2024, 06:52 UTC

Acquisities, Fusies, Overnames

Lonza Streamlines Organizational Structure

24 okt 2024, 05:40 UTC

Winsten

Lonza Expects Accelerating Sales Growth in Final Quarter

29 jan 2025, 08:11 UTC

Marktinformatie
Winsten

Lonza's Outlook Looks Positive -- Market Talk

29 jan 2025, 07:22 UTC

Marktinformatie
Winsten

Lonza Had a Mixed Year Across Divisions -- Market Talk

29 jan 2025, 07:11 UTC

Marktinformatie
Winsten

Lonza's Results Don't Contain Any Surprises -- Market Talk

29 jan 2025, 06:26 UTC

Top Nieuws
Winsten

Lonza Posts Lower Sales, Earnings But Expects Capsules Business Rebound This Year

16 jan 2025, 10:32 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Lonza's Midterm Outlook Is Positive -- Market Talk

16 dec 2024, 22:03 UTC

Top Nieuws

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

13 dec 2024, 08:07 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Lonza Unlikely to Pursue Large Acquisitions -- Market Talk

12 dec 2024, 08:51 UTC

Marktinformatie
Winsten
Acquisities, Fusies, Overnames

Lonza's Exit of Capsules Business Is a Positive Move -- Market Talk

12 dec 2024, 08:02 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Lonza's Divestiture of Capsules Division Shouldn't Surprise -- Market Talk

12 dec 2024, 05:59 UTC

Acquisities, Fusies, Overnames

Lonza Targets Dividend Pay-Out Ratio Between 35%-45%

12 dec 2024, 05:59 UTC

Acquisities, Fusies, Overnames

Lonza Confirms Div Policy; to Maintain or Increase Div Per Shr Year-on-Year

12 dec 2024, 05:58 UTC

Acquisities, Fusies, Overnames

Lonza Sees Low-To-Mid Single-Digit CER Sales Growth Beyond 2025

12 dec 2024, 05:58 UTC

Acquisities, Fusies, Overnames

Lonza Sees CHI Core Ebitda Margin in the Mid-Twenties for 2025

12 dec 2024, 05:58 UTC

Acquisities, Fusies, Overnames

Lonza Sees Gradual Return to Previous Core Ebitda Margin Beyond 2025

12 dec 2024, 05:57 UTC

Acquisities, Fusies, Overnames

Lonza Sees Low-To-Mid Single-Digit CHI Sales Growth for 2025

12 dec 2024, 05:55 UTC

Acquisities, Fusies, Overnames

Lonza Sees Core 2025 Ebitda Growth Ahead of Sales Growth

12 dec 2024, 05:54 UTC

Acquisities, Fusies, Overnames

Lonza CHF 2025 Sales From Vacaville, Core Ebitda Margin Approaching 30%

12 dec 2024, 05:54 UTC

Acquisities, Fusies, Overnames

Lonza CDMO 2025 Outlook Approaching 20% Sales Growth in CER

12 dec 2024, 05:53 UTC

Acquisities, Fusies, Overnames

Lonza Sees 2024 Core Ebitda Margin of 27-29%

12 dec 2024, 05:53 UTC

Acquisities, Fusies, Overnames

Lonza Sees Flat 2024 CER Sales Growth

12 dec 2024, 05:52 UTC

Acquisities, Fusies, Overnames

Lonza Backs 2024 View

12 dec 2024, 05:52 UTC

Acquisities, Fusies, Overnames

Lonza: CDMO Business to Be Structured Into Three New Business Platforms

12 dec 2024, 05:52 UTC

Acquisities, Fusies, Overnames

Lonza to Exit Capsules, Health Ingredients Business at Appropriate Time

12 dec 2024, 05:51 UTC

Acquisities, Fusies, Overnames

Lonza Outlines Strategy, New Organizational Structure and Guidance

24 okt 2024, 06:37 UTC

Marktinformatie
Winsten

Lonza 3Q Update Didn't Surprise -- Market Talk

Peer Vergelijking

Prijswijziging

Lonza Group AG Prognose

Koersdoel

By TipRanks

23.88% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 670.94 CHF  23.88%

Hoogste 744 CHF

Laagste 625 CHF

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Lonza Group AG - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

9

Buy

2

Hold

0

Sell

Sentiment

By Acuity

10 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.